Systematical Mutational Analysis of FRATtide against Osteoclast Differentiation by Alanine Scanning.

Osteoporosis, a global bone disease, results in decreased bone density, mass, and microarchitecture deterioration, increasing fracture risk. In previous research, FRATtide, a peptide derived from a glycogen synthase kinase-3 binding protein, effectively hindered osteoclast differentiation to yield therapeutically potent derivatives via single and double stapling. However, FRATtide's structure-activity relationship remains unclear. This study synthesized 25 FRATtide-derived peptides through systematic alanine scanning and evaluated their activities. Substitutions in Pro 2 , Leu 5 , Leu 9 , Val 10 , Leu 11 , Ser 12, Asn 14 , Leu 15 , Ile 16 , Glu 18 , Arg 22 , Ser 25 , and Arg 26 showed reduced activity, while FRT13 and FRT20 with Gly 13 and Arg 21 substitutions, respectively, displayed enhanced activities. F-actin binding and bone resorption assays on FRT13 and FRT20 showed better inhibition of osteoclast differentiation and bone resorption compared with FRATtide. This study elucidated FRATtide's structure-activity relationship, thereby facilitating future structural optimization for osteoporosis treatment.